DOI: 10.1055/s-00034925

Hämostaseologie

LinksClose Window

References

ITAC (INSIGHT 013) Study Group.
Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.

Lancet 2022;
399 (10324): 530-540

ITAC (INSIGHT 013) Study Group.
Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.

Lancet 2022;
399 (10324): 530-540

Download Bibliographical Data

Access:
Access:

We do not assume any responsibility for the contents of the web pages of other providers.